Gao J
The antimalarial drug chloroquine phosphate which has already been approved is confirmed to have an anti-2019-nCoV effect and has been included in diagnostic and
We found that treatment with hydroxychloroquine is associated with increased mortality in COVID-19 patients, and
A worker checking the production of chloroquine phosphate in China last month
Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
However, according to a recent study, three new oral antivirals
Caused by a new virus, SARS-CoV2, COVID-19 is related to the common cold and the SARS-CoV1 virus that was responsible for the 2003 Severe Acute Respiratory Syndrome (SARS) infection in Asia, causing about
Disclaimer: the article has not been peer-reviewed; it should not replace individual clinical judgement and the sources cited should be checked
10 There has been particular interest surrounding the use of antivirals with anti-inflammatory properties, as it has been proposed that the ARDS seen in COVID-19 patients could be a result of a cytokine storm when the immune system Several clinical trials in China have shown chloroquine phosphate, an aminoquinoline used in malaria treatment, to be effective against COVID-19 at a dose of 500 mg/day
Chloroquine (CQ) and hydroxychloroquine (HCQ) have been used in the treatment and prophylaxis of a number of conditions, such as malaria, for several years
Conventional therapy: Not yet recruiting
No effective prophylactic or post-exposure therapy is currently available
Results We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells
ARALEN, chloroquine phosphate, USP, is a 4-aminoquinoline compound for oral administration
The anti-malarial drug Chloroquine (CQ) and its derivative hydroxychloroquine have shown antiviral activities in vitro against many viruses, including coronaviruses, dengue virus and the biosafety level 4 Nipah and Hendra paramyxoviruses
Initial dose of 1 g of chloroquine phosphate (600 mg of chloroquine) followed by 500 mg of chloroquine phosphate (300 mg of chloroquine) given at 6, 24, and 48 hours after initial dose
613 is used for converting to chloroquine phosphate) Parasitic diseases: WHO, 2020: 6* 500 mg daily for 2–10 days
Chloroquine and hydroxychloroquine of chloroquine phosphate in a FDA’s EUA authorizes the use of chloroquine and hydroxychloroquine from the SNS for treatment of COVID-19 only, not for other indications (e